Rouet F., Chaix M.-L., Nerrienet E., Ngo-Giang-Huong N., Plantier J.-C., Burgard M., Peeters M., Damond F., Ekouevi D.K., Msellati P., Ferradini L., Rukobo S., Maréchal V., Schvachsa N., Wakrim L., Rafalimanana C., Rakotoambinina B., Viard J.-P., Seigneur
Laboratoire de Virologie, Centre Muraz, Bobo-Dioulasso, Burkina Faso; Laboratoire de Virologie, Université René Descartes, CHU Necker-Enfants Malades, Paris, France; HIV/Hepatitis Laboratory, Pasteur Institute, Phnom Penh, Cambodia; Laboratoire de Virologie, Centre Pasteur du Cameroun, Yaoundé, Cameroon; Institut de Recherche Pour Le Développement, URI 174, Muang, Chiang Mai, Thailand; Laboratoire de Virologie, EA 2656, CHU C. Nicolle, Rouen, France; Laboratoire Rétrovirus, UMR145, Institut de Recherche Pour Le Développement, Montpellier, France; Laboratoire de Virologie, Hôpital Bichat, Paris, France; Programme PAC-CI, Abidjan, Cote d'Ivoire; UMR 145, Institut de Recherche Pour Le Développement, Bobo-Dioulasso, Burkina Faso; Epicentre, Paris, France; ZVITAMBO Project, Borrowdale, Harare, Zimbabwe; Institut Pasteur, Bangui, Central African Republic; Centro Nacional de Referencia para El SIDA, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina; Institut Pasteur, Casablanca, Morocco; Laboratoire de Bactériologie, CHUA, Hópital Joseph Ravoahangy Andrianavalona, Antananarivo, Madagascar; Service des Maladies Infectieuses, CHU Necker-Enfants Malades, Paris, France; Laboratoire de Virologie, CHU Michallon, Grenoble, France; Centre Muraz, Laboratoire de Virologie, BP 390, Bobo-Dioulasso 01, Burkina Faso
Rouet, F., Laboratoire de Virologie, Centre Muraz, Bobo-Dioulasso, Burkina Faso, Centre Muraz, Laboratoire de Virologie, BP 390, Bobo-Dioulasso 01, Burkina Faso; Chaix, M.-L., Laboratoire de Virologie, Université René Descartes, CHU Necker-Enfants Malades, Paris, France; Nerrienet, E., HIV/Hepatitis Laboratory, Pasteur Institute, Phnom Penh, Cambodia, Laboratoire de Virologie, Centre Pasteur du Cameroun, Yaoundé, Cameroon; Ngo-Giang-Huong, N., Institut de Recherche Pour Le Développement, URI 174, Muang, Chiang Mai, Thailand; Plantier, J.-C., Laboratoire de Virologie, EA 2656, CHU C. Nicolle, Rouen, France; Burgard, M., Laboratoire de Virologie, Université René Descartes, CHU Necker-Enfants Malades, Paris, France; Peeters, M., Laboratoire Rétrovirus, UMR145, Institut de Recherche Pour Le Développement, Montpellier, France; Damond, F., Laboratoire de Virologie, Hôpital Bichat, Paris, France; Ekouevi, D.K., Programme PAC-CI, Abidjan, Cote d'Ivoire; Msellati, P., UMR 145, Institut de Recherche Pour Le Développement, Bobo-Dioulasso, Burkina Faso; Ferradini, L., Epicentre, Paris, France; Rukobo, S., ZVITAMBO Project, Borrowdale, Harare, Zimbabwe; Maréchal, V., Institut Pasteur, Bangui, Central African Republic; Schvachsa, N., Centro Nacional de Referencia para El SIDA, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina; Wakrim, L., Institut Pasteur, Casablanca, Morocco; Rafalimanana, C., Laboratoire de Bactériologie, CHUA, Hópital Joseph Ravoahangy Andrianavalona, Antananarivo, Madagascar; Rakotoambinina, B., Laboratoire de Bactériologie, CHUA, Hópital Joseph Ravoahangy Andrianavalona, Antananarivo, Madagascar; Viard, J.-P., Laboratoire de Virologie, Université René Descartes, CHU Necker-Enfants Malades, Paris, France, Service des Maladies Infectieuses, CHU Necker-Enfants Malades, Paris, France; Seigneurin, J.-M., Laboratoire de Virologie, CHU Michallon, Grenoble, France; Rouzioux, C., Laboratoire de Virologie, Université René Descartes, CHU Necker-Enfants Malades, Paris, France
The high genetic diversity of HIV-1 has a major impact on the quantification of plasma HIV-1 RNA, representing an increasingly difficult challenge. A total of 898 plasma specimens positive for HIV-1 RNA by commercial assays (Amplicor v1.5; Roche Diagnostic Systems, Alameda, CA or Versant v3.0; Bayer Diagnostics, Emeryville, CA) were tested using the Agence Nationale de Recherches sur le SIDA second-generation (G2) real-time reverse transcriptase polymerase chain reaction (RT-PCR) test: 518 samples containing HIV-1 of known subtype, including 88 from 2 subtype panels and 430 harboring B (n = 266) and non-B (n = 164) group M HIV-1 subtypes from patients followed up in 2002 through 2005 at Necker Hospital (Paris, France), and 380 samples from 10 different countries (Argentina, Cambodia, Cameroon, Central African Republic, France, Ivory Coast, Madagascar, Morocco, Thailand, and Zimbabwe). HIV-1 RNA values obtained by G2 real-time PCR were highly correlated with those obtained by the Amplicor v1.5 for B and non-B subtypes (R = 0.892 and 0.892, respectively) and for samples from diverse countries (R = 0.867 and 0.893 for real-time PCR vs. Amplicor v1.5 and real-time PCR vs. Versant v3.0, respectively). Approximately 30% of specimens harboring non-B subtypes were underquantified by at least -0.51 log10 in Amplicor v1.5 versus 5% underquantified in G2 real-time PCR. Discrepant results were also obtained with subtype B samples (14% underquantified by Amplicor v1.5 vs. 7% by G2 real-time PCR). Similar percentages were observed when comparing results obtained with the G2 real-time PCR assay with those obtained using the Versant assay. Addressing HIV-1 diversity, continual monitoring of HIV-1 RNA assays, together with molecular epidemiology studies, is required to improve the accuracy of all HIV RNA assays. © 2007 Lippincott Williams & Wilkins, Inc.